Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

OBJECTIVES: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. METHODS: We undertook a dose-escalating, open-label, randomized-controlled (...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoo, Saye H, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren, Tansley-Hancock, Olana, Greenhalf, William, Woods, Christie, Reynolds, Helen, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria, Owen, Andrew, Lalloo, David G, Jacobs, Michael, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598307/
https://www.ncbi.nlm.nih.gov/pubmed/34450619
http://dx.doi.org/10.1093/jac/dkab318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598307/
https://www.ncbi.nlm.nih.gov/pubmed/34450619
http://dx.doi.org/10.1093/jac/dkab318

Ejemplares similares